24/7 Market News Snapshot 31 Jul 2024 – Bionomics Limited American Depository Shares (NASDAQ: BNOX)

July 31, 2024 6:02

Press Release

DENVER, Colo., 31 July, 2024 (247marketnews.com) – (Nasdaq:BNOX) are discussed in this article.
Bionomics Limited American Depository Shares (BNOX) experienced a significant pre-market surge, soaring to $1.146 from the previous close of $0.834, marking an impressive 45.67% increase. With trading volume reaching 1.4 million, this bullish momentum indicates strong investor confidence and hints at substantial potential gains for the company.

This surge follows the positive outcome of a pivotal End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of Bionomics’ flagship drug, BNC210, into Phase 3 trials for Post-Traumatic Stress Disorder (PTSD) treatment. The FDA’s endorsement highlights the considerable efficacy and safety demonstrated by BNC210 in the recent Phase 2b ATTUNE study, which targeted the challenging symptoms of PTSD, a condition with significant unmet medical needs.

Bionomics’ CEO, Dr. Errol De Souza, emphasized the importance of the FDA’s supportive stance, stating, “The positive feedback from our EoP2 meeting underscores the significant advancements we have made with BNC210. Our team is more committed than ever to developing transformative treatments for CNS disorders, and the FDA’s endorsement propels us closer to delivering an impactful new therapy for PTSD patients.”

As Bionomics approaches Phase 3 trials, the company continues to focus its strategic and operational efforts on the successful delivery of its treatment pipeline. This milestone not only underscores Bionomics’ dedication to innovative research but also offers a glimmer of hope for patients suffering from PTSD.

Stakeholders are encouraged to stay informed through Bionomics’ official communications platforms for further updates on BNC210 and other groundbreaking developments. Bionomics remains at the forefront of biotechnology innovation, striving to set new standards in the treatment of central nervous system disorders.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.